Efficiency and the adverse effect of systematic corticosteroid therapy for atopic dermatitis

Banan Aedh Alfayi, Safiyh Ahmad Al-asiri, Lamyaa Omar Saad Al-Gelban, Sarah Abdullah Suliman, Malak Saleh Abdullah, Rawan Mari Alshehri, Bayan Nassir Asseri, Nour Khairan Alamri

Abstract:

This review sought to summarize the available evidence for using SCSs in Atopical dermatitis, it's safety, efficiency and adverse effect. PubMed, Embase, Medline, Scopus, Web of Science, and Cochrane Library were searched for relevant studies to Efficiency and the adverse effect of systematic corticosteroid therapy for atopic dermatitis that was published up to 2018. Systemic corticosteroids are often utilized to manage atopic dermatitis, but their safety and effectiveness has not been systematically evaluated. SCSs could be a valuable therapy of AD flares owing to their rapid induction of a clinical reaction, perceived short-term safety and tolerability, and low cost. Nonetheless, few studies have determined the efficacy and safeness of SCSs in AD. Due to significant adverse effects, consisting of rebound flaring, use of systemic corticosteroids must be limited to short courses as a bridge to steroid-sparing treatments.

Introduction:

Atopic dermatitis is a common, chronic, relapsing, inflammatory skin illness that mainly affects kids. Atopy is defined as an inherited propensity to produce immunoglobulin E (IgE) antibodies in response to minute quantities of typical ecological proteins such as plant pollen, home allergen,

and food irritants. Atopic dermatitis influences regarding one-fifth of all individuals during their life time, yet the occurrence of the illness differs significantly throughout the world [1] In a number of supposed developed countries, the prevalence enhanced considerably in between 1950 and 2000 a lot that several describe as the "allergic epidemic." However, current indications aim to eczema signs and symptoms having levelled off or also having actually reduced in some nations with a formerly really high prevalence, such as the United Kingdom and New Zealand [2].This indicates that the allergic disease epidemic is not boosting constantly worldwide. Nevertheless, atopic dermatitis stays a severe health issue, and in lots of countries, especially in the developing globe, the condition is still significantly growing.

The American Academy of Dermatology standards for therapy of atopic dermatitis (AD) advise a rated strategy, beginning with skin care and trigger evasion [3].In mild-tomoderate AD, topical corticosteroids or calcineurin inhibitors and disinfectant procedures are proper. Systemic therapy is suggested for relentless, moderate-to-severe AD after inadequate action to maximized topical management [4].A large range of treatment methods have been used for systemic corticosteroids (SCSs) in professional practice (eg, different deliveries, application, regularities, and periods). SCSs are typically used as a first-line systemic therapy of AD [5], [6] generally simply put training courses to subdue AD task and disturb flares [7].

This review sought to summarize the available evidence for using SCSs in Atopical dermatitis, it’s safety, efficiency and adverse effect.

Methodology:

PubMed, Embase, Medline, Scopus, Web of Science, and Cochrane Library were searched for relevant studies to Efficiency and the adverse effect of systematic corticosteroid therapy for atopic

dermatitis that was published up to 2018. References lists of relevant articles where searched for more supportive studies to our review.

Discussion:

Diagnosis and Clinical Presentation

The look of the private skin lesion in atopic dermatitis does not differ from other eczemas such as contact dermatitis. In its acute type, eczema is characterised by a dynamic red infiltrate with oedema, vesicles, exuding, and crusting; lichenification, excoriations, papules, and nodules dominate the subacute and chronic kind. As necessary, the diagnostic technique builds on other qualities such as the distribution of the dermatitis as well as linked attributes of the patient. The normal patient with atopic dermatitis is a person with:

- an very early start of itchy eczema localised at normal sites such as the flexures of the arm joints and knees in an atopic patient or in a individual with a familial predisposition to atopic illness.

In 1980 by Hanifin and Rajka were developed the most widely utilized diagnostic standards for atopic dermatitis and were later changed by the American Academy of Dermatology (Table 1) [8].

Table 1.Diagnostic criteria for atopic dermatitis.

Essential features
Itch
Eczema with typical morphology and age-specific pattern
Important features
Early age of onset
Atopy (personal or family history)
Dry skin
Associated features
Atypical vascular response (i.e., facial pallor, white dermographism)
Keratosis pilaris, palmar hyperlinearity, ichthyosis
Ocular and periorbital changes
Other regional findings (e.g., perioral and periauricular lesions)

Perifollicular accentuation, lichenification, and excoriations

In clinical practice this set of criteria is primarily useful; another set of diagnostic questions widely used in epidemiological research was developed by the UK Working Party in 1994 (Table 2) [9].

Table 2. Therapeutic approaches to atopic dermatitis.

Topical treatments
Corticosteroids
Calcineurin inhibitors
Phototherapy
Ultraviolet light A (UVA)
Ultraviolet light B (UVB)
Ultraviolet light A + Psoralene (PUVA)
Systemic treatments
Oral corticosteroids
Azathioprine
Cyclosporine A
Methotrexate

The severity of eczema can be graded according to several scoring systems such as SCORAD [10] and EASI [11].

- **Typical Manifestations**

The clinical performance of atopic dermatitis is usually more elaborate with a large variant in the morphology and distribution of the eczema integrated with numerous other features. Nevertheless, several patients with atopic dermatitis have a general propensity to present with dry skin (xerosis) due to the reduced water material and an too much water loss through the skin. The skin is light as a result of enhanced tension in the dermal capillaries and the ability to sweat is minimized. There is an increased cholinergic feedback to scrape, so-called white dermographism or skin-writing, resulting in hives at the afflicted site. The hands of the hands and feet may show hyperlinearity, and the individuals' hair is dry and fragile. Typically, there is a double skinfold underneath the

inferior eyelid (Dennie-Morgan layer) that becomes overstated in times of increased illness activity. The eye environments could be darkened because of postinflammatory hyperpigmentation.

Atopic dermatitis can be grouped into 3 clinical phases, although these could be difficult to duplicate in the private patient [2].

Atopic Dermatitis of Infancy

Infants experience eczema that is usually localized to the face, scalp, and extensor aspects of the arms and legs, yet it can likewise prevail. The lesions are characterised by erythema, papules, blisters, excoriations, exuding, and development of crusts.

Atopic Dermatitis of Childhood

In children and older kids, the dermatitis lesions often tend to shift place to ensure that they are often restricted to the flexures of the elbows and knees as well as the wrists and ankles, although it could occur at any type of site. Generally, the dermatitis ends up being drier and lichenified with excoriations, papules, and nodules.

Atopic Dermatitis of Adolescence and Adulthood

In grown-up patients, the lesions regularly localise to the face and neck, head-and-neck dermatitis, and a significant section of patients, around 30%, establish atopic hand dermatitis, which might interfere with work environment activities.

Irritating Factors

In several patients, atopic dermatitis takes a chronic, reverting course when it is not feasible to predict durations of activity or identify aggravating aspects. Nevertheless, lots of exposures, that

are aggravating the eczema should be prevented from contact and avoided. Woolen clothes, honey and pollen aggravate itching and pain for large number of patients. Warm water could also exacerbate itching, and long baths should be avoided. Numerous infections, significantly staphylococci, are regular root causes of exacerbations as various foods are, specifically in situations where a patient is sensitized to the food. Food evasion must be promoted just if a patient has recorded allergic reaction to a presumed food and out the basis of asymptomatic sensitization alone. Another phenomenon that can result in the eczema worsening is contact urticaria, which is a response adhering to skin exposure to a food, as an example, citrus fruits or tomatoes. The skin around the mouth is typically the site of such a reaction. Last but not least, many patients report that difficult living aggravates their eczema.

Differential Diagnoses

Numerous illness present with a skin breakout that resembles atopic dermatitis. Nonetheless, careful analysis of the morphology and localization of the rash combined with details regarding the individual patient normally leads to a diagnosis. Conditions that in some cases appear like atopic dermatitis are scabies, seborrheic dermatitis, and contact dermatitis.

- **Systematic corticosteroid therapy**

When systemic treatment is applied in moderate-to serious AD and various other inflammatory skin diseases, SCSs are among the medicines most commonly utilized. SCSs provide quick remedy for unbending itch in AD [13], [14].Yet, considerable voids exist, including optimum dose, frequency, and period of SCS therapy. With the restricted trials and little cohorts, there is poor evidence to guide clinical method on usage and dosing of SCSs.

Brief training courses are normally safe in dealing with acute and self-limited dermatoses. Nevertheless, limited data are available for AD specifically [15].Some medical professionals use SCSs for the initial control of serious inflammatory conditions prior to transitioning or" linking" to steroid-sparing agents [16], [15].Nonsteroidal agents commonly have delayed beginning of efficiency and require baseline blood work before initiation. Cyclosporine and oral tacrolimus might take 1 to 2 weeks for considerable renovation in skin disease, whereas mycophenolate mofetil, azathioprine, and methotrexate could take 4 to 12 weeks to attain performance. Dupilumab may additionally take a number of weeks to attain professional effectiveness. Anecdotally, SCSs are highly efficacious. Nevertheless, one of the only head-to-head RCTs done against cyclosporine in 38 adults with extreme AD found that cyclosporine was a lot more effective at accomplishing steady remission, with less rebound flaring [16]. Rebound flaring and/or getting worse of AD prevail anomalies after discontinuation of SCSs [16].Acute AEs of SCSs include mood disruptions, hypothalamic-pituitary-adrenal axis suppression, gastrointestinal upset, myopathies, liquid and sodium retention, weight gain, immunosuppression, impaired glucose tolerance, and damaged wound recovery (Table 1.)The most frequently identified and addressed AEs in AD include rebound flaring after discontinuation, hypothalamic-pituitary adrenal axis reductions, and growth retardation in youngsters. Lasting AEs are numerous and well established [15]. Reductions of the hypothalamic-pituitary adrenal axis can take place by 4 weeks and could be subclinical [15].One study showed considerable reduction in urinary cortisol after 1 month of therapy [17], [18].AI makes patients particularly vulnerable to stress connected with surgery or infection. AI might show up as weakness, exhaustion, fever, nausea, or anorexia, with hypotension and shock developing in extreme instances [15]. Tapering of brief courses (<1 week) of SCSs is most likely unnecessary; however, tapering is advised for longer programs to decrease risk for development of Adrenal insufficiency [13].A solitary morning dosage or alternate-day dosing of oral corticosteroids might

minimize suppression of the hypothalamic-pituitary adrenal axis [20], [21], [15].Alternate-day application utilizing an intermediate-acting steroid (eg, prednisone) could permit about 12 hours of hypothalamic pituitary-adrenal axis healing on the off day [19].Nevertheless, risk for osteoporosis, cataracts, and growth-retardation is connected to cumulative steroid application and is not alleviated by this application routine [20], [21], [15].No studies evaluating the impact of temporary subclinical HPA gain access to suppression were identified. One research study showed a considerable reduction in median development speed after 4 weeks of oral BDP treatment [18].Study subjects had only temporary follow-up, and the authors did not report whether rebound growth happened after cessation. Although SCSs are normally believed to be more powerful compared to topical corticosteroids, some think that higher concentrations in the superficial layers of the dermis are likely accomplished via topical formulations, with less AEs [18].Topical therapy is suggested prior to utilizing SCSs.

- **Safety and tolerability**

SCSs have many AEs(adverse-effect) limiting their use in AD (Table 3).

Rebound AD flares. One study of oral prednisone for extreme AD was ended early as a result of illness flares in 15 of 38 subjects [16].In all, 81% of patients managed with prednisolone had rebound of their AD contrasted with 65% of those treated with cyclosporine. A case series of 3 patients with severe AD successfully treated with SCSs found that they developed acute rebound flares after SCS cessation [25].One more research study of oral versus IM (methylprednisolone) reported regression and rebound flares 1 week after steroid discontinuation, without any long-lasting improvement in skin illness no matter administration [23].

Adrenal insufficiency.A systematic review of adrenal insufficiency (AI) (cortisol level, ≤ 500 nmol/L) after glucocorticoid usage determined 74 articles with 3753 participants with different medical diagnoses [26].Specific doses differed depending upon steroid selection. Meta-analysis showed a considerable increase in outright risk with medium- (1 month to 1 year) and long-term (> 1 year) use, in addition to with medium- and high-dose corticosteroids. Around half of patients had resolution of AI upon retesting at 28 days. Two studies took a look at the danger of AI in AD after use topical fluocinonide or clobetasol; 1 instance of temporary AI was reported; it settled upon retesting. Two RCTs of oral SCSs in childhood AD showed no significant AEs or relapses after 3 weeks of follow-up [31].An additional study showed that after 4 weeks of treatment, kids receiving oral BDP had reduced urine-free cortisol levels than their control counterparts, which is symptomatic of subclinical adrenal reductions [32].A research study of oral BDP in AD showed that 7 of 10 youngsters taking an upkeep dose had development disability after 6 months of treatment and numerical reduction in very early morning plasma cortisol degree and 24-hour urinary cortisol excretion [33].An empirical research reported that no patients showed signs or signs and symptoms of AI from IM TAC for numerous dermatoses [24].Total cortisol level lowered dramatically at 6 and 12 weeks versus standard with IM TAC, however imply early morning cortisol and ACTH degrees did not differ substantially [24].Tapering of SCSs was deemed unnecessary to reduce the risk of AI with programs lasting less compared to 1 week [27].Nevertheless, a 7-to 14-day or 15- to 30-day taper up until physiologic dosage (10 mg/m2/ d) was recommended for training courses of 2 to 3 or 4 or even more weeks, respectively.

Other AEs. Significant growth retardation happened in kids with serious AD treated with 4 weeks of oral BDP(beclomethasone dipropionate) therapy [33].Corticosteroid allergic reactions need to be considered in patients with treatment-refractory dermatitis sores, subacute contact dermatitis,

systemic contact dermatitis, or maculopapular exanthems [28].A number of AEs were observed with IM(intramuscular) TAC(triamcinolone acetonide), consisting of enhanced susceptibility to infection total and bacterial superinfection of skin (in specific, exacerbation of headache disorders, perimenopausal signs and symptoms, and peptic abscess illness) [23].Another study of IM TAC found no shot website degeneration, weight gain, hypertension, cushingoid look, hirsutism, pedal edema, very easy bruising, irregular menses, or mood or hunger modifications and lowered incidence of rebound worsenings [24].Intravenous methylprednisolone, 20 mg/kg/d for 3 days, in serious AD was not linked with observed infections. Some authors recommended alternate-day application of oral corticosteroids for children with severe generalized AD to reduce AEs. Others advised that if day-to-day dosing is necessary in children, oral corticosteroids ought to be given as 1 dose in the early morning to decrease development stunting [29].Ultimately, a research reported that regardless of treatment success with SCSs, patients rated their healthcare worse total and had lower fulfillment and poorer high quality of life [30].

Table 3. Adverse-effect limiting their use of SCSs in AD.

Adverse event	**Excess risk in patients with AD**
Rebound flare[10-30]	10/21 flared while taking prednisolone vs 5/17 while taking cyclosporine, requiring early termination[4].
Adrenal suppression [3],[29],[13-15].	24/26 had lower free urinary cortisol levels at 4 wk, resolved by wk 8 [29]. Decreased morning cortisol level and 24-h urine cortisol level[13]. Significant decrease in morning total cortisol level at 6 weeks (8.06 ± 2.17 mg/dL, normal morning level range 4-23 mg/dL, P <.01) and at 12 weeks (7.8 ± 1.69 mg/dL, P< .05) compared with baseline (10.54± 2.77 mg/dL) without signs or symptoms of adrenal insufficiency[14]. AR for adrenal suppression of 487.7 (95% CI: 36.9-60.6)[15] · Short-term (<4 wk) AR of 1.4 (95% CI 0.3-7.4) d · Medium-term (1 mo to 1 y) AR of 11.9 (5.8-23.1) · Long-term (>1 y) AR of 27.4 (17.7-39.8) · Low-dose AR of 2.4 (0.6-9.3) · Medium-dose AR of 8.5 (4.2-16.8) · High-dose AR of 21.5 (12.0-35.5)
Hypertension [18],[5],[31],[3]	3/21 (10%)[4]

Nausea/vomiting/GERD/PUD [4],[6]	1/73 (1.4%)[6]
Weight gain [3],[4],[31].	2/21 (10%)[4]
Opportunistic infections/immunosuppression [3],[29].	1/21 (4%)[4] 1/73 (1.4%)[6]
Growth retardation (children) [3],[5],[8],[17],[18].	Wilcoxon signed rank test (95% CI 0.3-1.03)[13]
Hyperlipidemia[4]	4/21 (19%)[4]
Elevated liver function test results [4]	2/21 (10%)[4]

PUD- peptic ulcer disease, GERD -gastroesophageal reflux disease; CI, confidence interval; AR, absolute risk

Conclusion:

Systemic corticosteroids are often utilized to manage atopic dermatitis, but their safety and effectiveness has not been systematically evaluated. SCSs could be a valuable therapy of AD flares owing to their rapid induction of a clinical reaction, perceived short-term safety and tolerability, and low cost. Nonetheless, few studies have determined the efficacy and safeness of SCSs in AD. Due to significant adverse effects, consisting of rebound flaring, use of systemic corticosteroids must be limited to short courses as a bridge to steroid-sparing treatments.

Reference:

1. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases

One and Three repeat multicountry cross-sectional surveys. The Lancet. 2006;368(9537):733–743.
2. Williams HC. Atopic dermatitis. New England Journal of Medicine. 2005;352(22):2314–2366.
3. Werfel T, Schwerk N, Hansen G, Kapp A. The diagnosis and graded therapy of atopic dermatitis. Dtsch Arztebl Int. 2014; 111:509-520.
4. Schmitt J, Schakel K, Folster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162:661-668.
5. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy. 2014;69:46-55.
6. Stroud GM, Miller RE, Kozikoski ES. Oral versus intramuscular methylprednisolone. A double-blind study. Arch Dermatol. 1963;1963:710-714.
7. Forte WC, Sumits JM, Rodrigues AG, Liuson D, Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunnopath. 2005;33:301-311.
8. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association 'Administrative Regulations for Evidence-Based Clinical Practice Guidelines' Journal of the American Academy of Dermatology. 2004;50:391–404.
9. Williams HC, Burney PGJ, Hay RJ, et al. The U.K. Working party's diagnostic criteria for atopic dermatitis—I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology. 1994;131(3):383–396.
10. Stalder JF, Taieb A, Atherton DJ, et al. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.
11. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11–18.
12. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. British Journal of Dermatology. *2010*;163(1):12–26.
13. Aylett SE, Atherton DJ, Preece MA. The treatment of difficult atopic dermatitis in childhood with oral beclomethasone diproprionate. Acta Derm Venereol (Stockh). 1992;1992: 123-125.
14. Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69:297-306.
15. Reddy S, Ananthakrishnan S, Garg A. A prospective observational study evaluating hypothalamic-pituitary-adrenal axis alteration and efficacy of intramuscular triamcinolone acetonide for steroid-responsive dermatolgoic disease. J Am Acad Dermatol. 2013;69:226-231.
16. Misery L. Therapeutic perspectives in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41:267-271.
17. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology and treatment. Immunol Allergy Clin North Am. 2015;35:161-183.

18. Vestergaard C, Deleuran M. Advances in the diagnosis and therapeutic management of atopic dermatitis. Drugs. 2014; 74:757-769.
19. Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016;16:75-85.
20. BuBmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis. J Dtsch Dermatol Ges. 2009;7: 205-219.
21. Heddle RJ, Soothill JF, Bulpitt CJ, Atherton DJ. Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: a randomized controlled trial. Br Med J (Clin Res Ed). 1984;289:651-654.
22. Werfel T, Schwerk N, Hansen G, Kapp A. The diagnosis and graded therapy of atopic dermatitis. Dtsch Arztebl Int. 2014; 111:509-520.
23. Pua VS, Barnetson RS. Recent developments in the treatment of adult atopic dermatitis. Australas J Dermatol. 2006;47: 84-89.
24. Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53:S3-S16.
25. Roos TC, Geuer S, Roos S, Brost H. Recent advances in treatment strategies for atopic dermatitis. Drugs. 2004;64: 2639-2666.
26. Barnetson RS, Rogers M. Childhood atopic eczema. BMJ. 2002;324:1376-1379.
27. Correale CE, Walker C, Murphy L, Craig TJ. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician. 1999; 60:1191-1198.
28. Susac A, Babic S, Lipozencic J. An overview on atopic dermatitis in children. Acta Dermatovenerol Croat. 2007;15: 158-166.
29. Heddle RJ, Soothill JF, Bulpitt CJ, Atherton DJ. Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: a randomized controlled trial. Br Med J (Clin Res Ed). 1984;289:651-654.
30. Notaro ER, Sidbury R. Systemic agents for severe atopic dermatitis in children. Paediatr Drugs. 2015;17:449-457.
31. Akhavan A, Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg. 2008; 27:151-155.
32. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology and treatment. Immunol Allergy Clin North Am. 2015;35:161-183.
33. Vestergaard C, Deleuran M. Advances in the diagnosis and therapeutic management of atopic dermatitis. Drugs. 2014; 74:757-769.